Videos

Panelists discuss how advanced practice providers (APPs) implement effective monitoring strategies for patients with chronic myeloid leukemia (CML), including regular check-ins after starting new medications such as nilotinib, encouraging patients to maintain symptom journals, and providing holistic care that addresses both physical symptoms and emotional well-being to help patients successfully navigate life with a chronic disease.

Panelists discuss how advanced practice providers (APPs) serve as crucial touchpoints throughout the journey of patients with chronic myeloid leukemia (CML), offering more accessible communication, early identification of adverse effects, medication management support, and integration of comprehensive supportive care services that collectively reduce emotional and logistical stress while improving overall quality of life.

According to a nurse practitioner who works in myeloma research, nurses and APPs are responsible for much of the clinical work with patients involved in trials.

Panelists discuss how cardiovascular toxicity remains a significant concern with certain tyrosine kinase inhibitors (TKIs) used in chronic myeloid leukemia (CML) treatment, particularly with the older nilotinib formulation that showed increased cardiotoxicity in long-term trials, though it remains unclear whether this was directly related to poor adherence to fasting guidelines or inherent to the medication's pharmacological properties.

Panelists discuss how eliminating the strict mealtime restrictions with the new nilotinib formulation addresses a significant unmet need in chronic myeloid leukemia (CML) treatment by reducing disruption to patients' daily lives, potentially improving medication adherence and overall quality of life for patients who otherwise face a normal life expectancy when their condition is properly controlled.

The intersection of cardiology and oncology is greater than nurses and providers may assume, explained 2 experts.

Danielle Fournier, DNP, APRN, AGPCNP-BC, AOCNP, discusses the role of oncology nurses in genomic testing.

Nurse practitioners should listen to patients’ concerns and be ready with questions when it comes to germline testing, according to an expert.

Panelists discuss how the new FDA-approved formulation of nilotinib offers significant advantages over the original version by eliminating fasting requirements, potentially improving patient adherence while maintaining efficacy and reducing the risk of toxicity-related complications such as glucose metabolism issues, elevated cholesterol, and pancreatitis.

Oncology nurses and APPs can enhance patients’ comfort by counseling patients on what integrative care is and working to make those options accessible.

Panelists discuss how chronic myeloid leukemia (CML) treatment has evolved over the past 5 years, highlighting advancements in tyrosine kinase inhibitor (TKI) therapy, improved adverse effect management, tailored treatment approaches through molecular monitoring, and increased emphasis on shared decision-making with patients.

Using liquid biopsies to test for ESR1 mutations in breast cancer is more feasible for patients and has quicker turnaround times.

Practicing at top of licensure can create opportunities for oncology APPs to engage with patients and other providers in new ways.

Experts discuss how, it is crucial to approach treatment strategies with both compassion and transparency. It is important to explain the complexity of the situation and maintain clear and accessible language when discussing treatment strategies with patients and their families.

Experts discuss how, there is a role for SRS in treating brain metastases such as if a patient were to have a large singular brain metastasis that is causing symptoms such as seizures of neurological decline, that SRS could be a warranted treatment.

Working with patients in new contexts can provide meaning for oncology PAs, potentially reducing burnout, according to Eric Tetzlaff, MHS, PA-C, DFAAPA.

Katherine Cohen, MSN, FNP-C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.

Experts discuss optimizing renal cell carcinoma (RCC) treatment by integrating patient-reported outcomes and clinician insights.

Experts discuss patient-reported outcomes from the TiNivo-2 trial, focusing on quality of life and the treatment experience.

Experts discuss survival data from the TiNivo-2 phase 3 trial and practical approaches to dose management in clinical practice.

Experts discuss optimizing VEGFR-tyrosine kinase inhibitor (TKI) therapy, focusing on patient selection and management strategies in the clinical setting.

Experts discuss the efficacy profile of tivozanib monotherapy and clinical management strategies in advanced renal cell carcinoma (RCC).

Experts discuss the rational treatment selection of the VEGFR-tyrosine kinase inhibitor (TKI) tivozanib following progression after immune checkpoint inhibitor (ICI) therapy.

Documentation is especially important for nurse practitioners in cancer research and can lead to improved patient recruitment, says an expert.

Experts discuss sequencing strategies in renal cell carcinoma (RCC), focusing on optimizing treatment selection after immune-oncology (IO)–based therapy.

Experts discuss first-line treatment strategies for renal cell carcinoma (RCC) in 2025, navigating the evolving therapeutic landscape.

Experts discuss how, nearly half of patients diagnoses with HER-2 positive metastatic brain cancer do develop brain metastasis. It is thought that larger molecule treatments such as the monoclonal antibodies likely do not cross an intact blood brain barrier which is often why patients develop brain metastases